Open House Originale Agreement for Vericiguat
Oryginalny tytuł ogłoszenia
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-24 - Vericiguat
Ocena szansy
Skąd ta ocena?
Szansa
46 / 100
Złożoność
58 / 100
Czynniki ryzyka
Offers/contracts cannot be submitted via the portal; the notice says portal submission is technically not possible and...
Participation is limited to pharmaceutical undertakings with the required AMG status, seat location, authorisation, and...
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Przegląd
Moderate opportunityKluczowe fakty
- Supplies contract
- 1 lot
- Duration until Sep 2027
- Supply/rebate agreement for pharmaceutical products, specifically the active substance Vericiguat.
- Open House arrangement with uniform contractual conditions for all eligible participants.
Pokaż pełne podsumowanie
This is a German Open House supply arrangement for Vericiguat (CPV 33600000 Pharmaceutical products) led by Techniker Krankenkasse, with hkk and HEK listed as participating buyers. It is not a classic competitive award procedure: all eligible pharmaceutical companies meeting the stated conditions may join during the contract period, with no exclusivity and no individual negotiations. The contract term is up to 24 months from 01.10.2025 to 30.09.2027, with automatic earlier end if patent/market exclusivity expires. No contract value is stated. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the procurement documents are available electronically but were not analyzed in extracted text beyond the notice.
Ryzyka
Offers/contracts cannot be submitted via the portal; the notice says portal submission is technically not possible and...
Participation is limited to pharmaceutical undertakings with the required AMG status, seat location, authorisation, and...
Analiza może być niepełna
Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.
Kluczowe wymagania
Technical
- Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the relevant medicinal product.
- Applicant must have its seat in Germany, another EU Member State, or an EEA State.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product and/or otherwise be entitled to place it on the market in its own name.
Zamawiający
Lokalizacja
Hamburg, DEU
Strona
Identyfikator
992-80116-93
Działalność
Health
Części (1)
LOT-0001
Open House Originale Agreement for Vericiguat
Open House supply arrangement for the active substance Vericiguat. The notice states that all suitable pharmaceutical companies may conclude a rebate agreement under Section 130c(1) SGB V. No exclusivity, no individual negotiations, and uniform conditions apply. The lot is nationwide in Germany.
Lokalizacja
Czas trwania
Kategoria
Termin
Szczegóły kryteriów
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Vericiguat zu schließen.
Uwaga do wartości
Pokaż oryginalne dane TED
Oryginalny tytuł części
Open House Originale Rabattverträge 2025-24 - Vericiguat
Oryginalny opis TED
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Vericiguat zu schließen.
Szczegóły zamówienia
- Data publikacji
- 18 Aug 2025
- Języki
- German
Metadane referencyjne
- Podstawa prawna
- 32014L0024
Identyfikatory referencyjne
- ID przetargu
- 540042-2025
Dokumenty (1)
Podobne przetargi
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Ocena szansy
Skąd ta ocena?
Szansa
46 / 100
Złożoność
58 / 100
Czynniki ryzyka
Offers/contracts cannot be submitted via the portal; the notice says portal submission is technically not possible and...
Participation is limited to pharmaceutical undertakings with the required AMG status, seat location, authorisation, and...
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications